The New York Academy of Sciences and the Mushett Family Foundation jointly sponsored a conference on June 19, 2009. The meeting, titled "Circadian Disruption and Cancer," was the first to systematically survey how the disruption of circadian rhythms in the body can affect cancer. Of some 10 000 genes surveyed in a recent genomewide study, 10% could be linked to some type of circadian control. 1 It is only to be expected, therefore, that research would find many ways in which circadian biology could affect health and disease. This conference brought together many pioneers in the field of circadian biology and cancer for a series of significant presentations that included both laboratory and clinical data. In addition, a poster session was included, which further broadened the bases of discussion. This special issue includes papers from most of the conference presenters; 2 articles based on poster presentations are also included. There are 3 parts to the issue, which are discussed below.
Part 1: The Clock, Circadian Disruption, and Cancer Risk and Progression
Elizabeth Filipski and Francis Levi of the French Institute for Medical Research (INSERM) discuss their development of an animal model, chronically jet-lagged mice, which provides a foundation for studying the implementation of circadian lifestyle interventions. Chronically jet-lagged mice show accelerated growth of transplanted tumors, in addition to typical manifestations of circadian disruption, such as altered body temperature rhythms. However, when these mice were given regularly timed access to food at their normal eating times, the circadian disruption decreased, as did the tumor growth rate. Meal timing thus appears to have the capacity to reentrain this distorted circadian rhythm. This certainly adds support to the study of circadian lifestyle interventions, potentially for both the prevention and the control of cancer.
Patricia Wood, of the University of South Carolina and the Dorn Veterans Administration Medical Center, along with her colleagues, studied the way in which the Period clock gene mutations promote cancer. They propose that the disruptions of each core circadian clock gene are not uniformly tumor promoting but that specific circadian clock gene expression disruptions promote cancer through specific biochemical pathways. Down regulation of Period genes (Per1 and Per2) increases cancer cell proliferation in part through accelerated b-catenin signaling. Per2 mutation also accelerates intestinal polyp formation in Apc Min/+ mice, supporting the role of Per2 gene as a tumor suppressor. In addition, increased b-catenin destabilizes PER2 protein. The implication of this is that circadian disruption depleting Per1 and/or Per2 gene expression will increase cancer incidence or growth and adversely affect outcome. This opens the possibility of Per clock genedirected therapies to prevent or slow cancer progression.
Xiaoming Yang and colleagues at the Dorn Veterans Administration Medical Center Medical Chronobiology Laboratory present their work on the effects of Per1 and Per2 on tumor growth in animals. Tumors in animals grow with clear circadian organization, to the point that tumor size waxes and wanes dramatically through the course of the day and night. When certain mutations are present, the times of usual peak cancer growth rate are shifted. This points to the need to take care in the timing of the measurement of tumor size in research situations. It also suggests that the optimal times of day for delivery of antineoplastic drugs may be shifted in tumors with particular Period gene mutations. Expression levels of the circadian genes Per2 and Rev-Erba are reduced in human cancer samples from patients with lymphomas and acute myeloid leukemia as well as in lymphoma cell lines. Gery Sigal and Philip Koeffler of Cedars-Sinai Medical Center at UCLA studied the C/EBP (CCAAT-enhancer-binding proteins) transcription factors, which are involved in hematopoietic cell growth and differentiation, and are altered in leukemia and other cancers. They have shown that Per2 and Rev-Erba are targets of C/EBP and that overexpression of these 2 genes in hematopoietic cancer cell lines results in growth inhibition and stimulation of apoptosis. This is a significant signal of circadian involvement in the hematopoietic cancers and points the way toward entirely novel circadian clock-targeted leukemia and lymphoma therapies.
Vihas Vasu and colleagues at the University of California, Davis examined Nr1D1, also known as Rev-Erba, based on a whole-genome search for mRNA related to the effects of cigarette smoking. Lung cancer-resistant and lung cancer-susceptible strains of mice were compared in this search for circadian influences on susceptibility to tobacco smoke damage. Rev-Erba expression was downregulated by both whole tobacco smoke and filtered smoke, suggesting that another of the many ill effects of tobacco smoke is dysregulation of normal, protective circadian rhythms in this target tissue.
Jaclyn Guess and colleagues in the Arnold School of Public Health at the University of South Carolina, as well as other institutions, analyzed blood samples, fatigue, sleep disruption, anxiety, and depression in patients undergoing colonoscopy. Of particular interest to these investigators was whether they could detect differences among patients with different Per3 clock gene variants. Per3 clock variants have been associated with sleep disorders, circadian preference, and breast cancer risk. This team found that circadian disruption was more frequent and severe in those patients with certain clock gene phenotypes. This multidisciplinary study is, thus, a significant contribution to our understanding of how clock genes may manifest themselves clinically and how specific, heritable clock gene polymorphisms may increase cancer risk.
Part 2: Light, the Pineal, Melatonin, Circadian Disruption and Cancer
Steven Hill and colleagues at Tulane University have studied the MT1 melatonin receptor and its effects in breast cancer. MT1 activation has several antitumor mechanisms in breast tissue, including regulating growth factor and gene expression, regulating clock genes, and inhibiting tumor cell invasion. An MT1 mammary knock-in transgenic mouse developed in their laboratory exhibits reduced mammary gland development and lower estrogen receptor-a expression. This adds another pathway to the growing list of antitumor mechanisms modulated by the MT1 receptor.
David Blask and colleagues at Tulane University summarize findings regarding the influence of melatonin on uptake of linoleic acid and its metabolism to 13-HODE (13-hydroxyoctadecadienoic acid), and the consequences of this process for tumor proliferation. 13-HODE is an important stimulant of tumor growth. Exposing rats bearing human breast cancer xenografts to even low levels of light at night causes the uptake of linoleic acid and 13-HODE formation to increase dramatically. Human breast cancer xenografts perfused with blood from women exposed to light at night also increases linoleic acid uptake and 13-HODE formation. Melatonin levels, which are suppressed by light at night, thus exert a circadian rhythm on important tumor growth effects of linoleic acid metabolism. The proliferative effects of linoleic acid have previously been discussed only in nutritional contexts in the literature. This demonstration of circadian effects on fatty acid metabolism expands our concept of the interaction of circadian and nutritional processes, and suggests that circadian dysregulation of food intake and metabolism may be important in stimulating cancer growth.
Russel Reiter and his colleagues at the University of Texas Health Sciences Center have contributed an article based on Reiter's warmly received keynote presentation at the conference. It is a cogent summary of the mechanisms through which chronodisruption, sleep deprivation, and melatonin suppression contribute to cancer. This article reviews studies ranging from the epidemiology of short sleep duration to the detailed analysis of specific clock genes and cancer. And after summarizing this literature, Reiter urges us to also think beyond cancer, touching on the effects of chronodisruption on diabetes and the obesity epidemic, as well as possibly attention deficit disorder and autism.
Part 3: Fighting Circadian Disruption and Using Circadian Organization to Fight Cancer
Georg Bjarnason and colleagues have used wrist actigraphy to monitor the circadian rest-activity cycles of cancer patients. In their contribution to this issue, they analyze a combined data set of more than 250 metastatic colorectal cancer patients who wore actigraphs and also completed a quality-of-life questionnaire to determine the relationship of circadian disruption to anorexia and fatigue. They are able to distinguish a symptom cluster of anorexia, fatigue, and circadian disruption among a group of patients. This symptom cluster may be a result of proinflammatory cytokines but may also represent the result of a vicious cycle of interaction of these 3 symptoms that is often implicated in the deterioration of advanced cancer patients. Such a symptom cluster may be considered a new therapeutic target in cancer treatment.
Keith Block and colleagues at the Block Center for Integrative Cancer Treatment present a comprehensive review of the clinical rationale and techniques for developing circadian-based lifestyle therapies. They survey the effects of diet, exercise, and mind-body therapies on circadian rhythms. They discuss how circadian disruption affects and is affected by cancer terrain factors-inflammation, oxidative stress, the insulin-IGF (insulin-like growth factor) axis, blood coagulation parameters, immunity, and stress hormones. They also discuss current use of circadian-based therapies in cancer treatment, with a case series demonstrating the impact of chronomodulated chemotherapy on side effects and treatment tolerance.
William Hrushesky and colleagues at the Medical Chronobiology Laboratory of the Dorn Veterans Administration Medical Center, as well as other institutions, give an overview of circadian-based interventions for cancer patients, largely from a clinical perspective. They include a detailed survey of circadian disruption in patients with advanced lung cancer. Decreased daily functioning, increased anxiety and depression, poor sleep, daytime fatigue, and poor quality of life are all aspects of this disruption. A tight correlation exists between the amount of actigraphically measured circadian disruption and nighttime sleep quality and quantity, daytime fatigue, reactive depression severity, and quality of life. Potential interventions that include both lifestyle strategies and small molecules that target the circadian clock are now being explored as ways to remedy this chronodisruption and improve outcomes for cancer patients. Using physiological and behavioral means to improve circadian integration among cancer patients should lighten the symptom burden of advanced cancer by integrating the cancer patient more completely and normally within the circadian environment. This has the potential to both improve the quality of life and extend life in these patients.
In addition to the articles from the Circadian Disruption and Cancer Conference, we also feature 3 other articles. Carlos Austerlitz and colleagues from East Carolina University review the topic of nutrition and orthomolecular supplementation for lung cancer patients. Nutritional imbalances can severely affect the quality and quantity of life of cancer patients, especially among lung cancer patients who are frequently compromised nutritionally. Amelioration of these imbalances through diet and supplements can affect patients both psychologically and physically, and the East Carolina University has carefully reviewed potential nutritional strategies for these patients. Jody Noe, a naturopathic doctor, has contributed a short review on the use of l-glutamine during chemotherapy to reduce mucositis as well as to possibly stave off cachexia. l-Glutamine has very interesting therapeutic properties and deserves further study, as this review shows. Finally, Daniel Rubin, and Berton, and Arthur Berkson revisit a case study published earlier in this journal, with updates on a protocol using intravenous a-lipoic acid in addition to low-dose naltrexone in pancreatic cancer patients. Three additional cases are included in this article, along with a discussion of possible mechanisms of action for the intervention.
We are very happy to announce that Integrative Cancer Therapies has received its first impact factor. The 2009 Thomson Reuters Journal Citation Reports listed Integrative Cancer Therapies with an impact factor of 2.26, an excellent showing for a first-time ranking in a specialized field. 2 We thank our authors, editorial staff, editorial boards, and the staff of our publisher, Sage, for this tremendous effort in establishing a high-quality journal that is increasingly sought out by an international audience in the field of integrative oncology practice and research.
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